Lilly’s Retatrutide Delivers ~25% Weight Loss in Phase 3
Daily Biopharma Digest — May 21, 2026
Lilly’s triple-agonist sets a new obesity benchmark while M&A and AI deals keep flowing. Today’s top developments:
- Eli Lilly’s retatrutide hit TRIUMPH-1 Phase 3 with 25.0% weight loss at 12 mg at 80 weeks (vs. 3.9% on placebo)
- Immunovant shares surged on positive arthritis trial data
- BioMarin’s Phase 3 CANOPY-HCH-3 of Voxzogo (vosoritide) in hypochondroplasia hit its endpoint (+2.33 cm/yr vs. placebo); sNDA planned Q3 2026
- Lilly acquired Engage Biologics for up to $202M for its Tethosome non-viral DNA delivery platform — its seventh acquisition since the start of 2026
- Incyte expanded its Genesis Molecular AI deal by $120M ($80M cash + $40M equity, ≥5 new targets) and partnered with Edison Scientific on the Kosmos AI platform
What to Watch
- Obesity Drug Arms Race — Retatrutide’s 25% bar pressures Novo Nordisk and rivals to show superior or differentiated efficacy.
- AI Implementation at Scale — BMS-Anthropic and Incyte deals signal pharma moving from pilots to enterprise AI deployments through 2026-2027.
- FcRn Class Competition — Immunovant’s arthritis data adds momentum to FcRn antagonists chasing autoimmune indications beyond rare diseases.
- Wearables Regulatory Scrutiny — The unresolved Whoop-FDA blood pressure dispute points to tighter enforcement across consumer health devices.